$福泰制药(VRTX)$ Phase 2 study of VX-814 in patients with alpha-1 antitrypsin deficiency discontinued based upon safety and pharmacokinetic data -

- Phase 2 study of VX-864 continues to enroll and dose patients; data expected in H1 2021 -

死掉一个二期临床的814，还是治AATD的。。这个我觉得情绪大于实质。反正也是套住了，就继续套吧。